US5152783A - Antithrombogenic material - Google Patents

Antithrombogenic material Download PDF

Info

Publication number
US5152783A
US5152783A US07/570,614 US57061490A US5152783A US 5152783 A US5152783 A US 5152783A US 57061490 A US57061490 A US 57061490A US 5152783 A US5152783 A US 5152783A
Authority
US
United States
Prior art keywords
antithrombogenic
ions
silicone material
functional groups
sioh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/570,614
Inventor
Yoshiaki Suzuki
Masahiro Kusakabe
Iwaki Masaya
Kiyoko Kusakabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sony Corp
RIKEN- Institute of Physical and Chemical Research
Original Assignee
Sony Corp
RIKEN- Institute of Physical and Chemical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP1-250523 priority Critical
Priority to JP1250523A priority patent/JP2930329B2/en
Application filed by Sony Corp, RIKEN- Institute of Physical and Chemical Research filed Critical Sony Corp
Assigned to SONY CORPORATION, A CORP. OF JAPAN, RIKAGAKU KENKYSHO reassignment SONY CORPORATION, A CORP. OF JAPAN ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: IWAKI, MASAYA, KUSAKABE, KIYOKO, KUSAKABE, MASAHIRO, SUZUKI, YOSHIAKI
Application granted granted Critical
Publication of US5152783A publication Critical patent/US5152783A/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0076Chemical modification of the substrate
    • A61L33/0082Chemical modification of the substrate by reacting with an organic compound other than heparin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C59/00Surface shaping of articles, e.g. embossing; Apparatus therefor
    • B29C59/16Surface shaping of articles, e.g. embossing; Apparatus therefor by wave energy or particle radiation, e.g. infra-red heating
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/08Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould by wave energy or particle radiation
    • B29C35/0866Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould by wave energy or particle radiation using particle radiation
    • B29C2035/0872Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould by wave energy or particle radiation using particle radiation using ion-radiation, e.g. alpha-rays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2083/00Use of polymers having silicon, with or without sulfur, nitrogen, oxygen, or carbon only, in the main chain, as moulding material

Abstract

An antithrombogenic material having its surface modified by ion implantation is disclosed. This antithrombogenic material may, for example, be a silicone material which has its surface modified by introducing functional groups on its surface by ion implantation. The material exhibits improved compatibility to blood due to introduction of the functional groups by ion implantation and the doping effect of the implanted elements.

Description

BACKGROUND OF THE INVENTION

This invention relates to an antithrombogenic material employed in artificial biocompatible material, such as an artificial blood vessel, or in medical equipment brought into contact with blood.

Recently, with the progress in medical technology, evolution of artificial or prosthetic organs having the function similar to that of a living body is progressing. For example, a medical equipment through which the blood from the living body is caused to flow transiently, such as an artificial dialysis system, or artificial organs, such as artificial blood vessel or artificial heart, are being put to practical usage.

Among the properties required of these medial equipment and artificial organs are biocompatibility and, above all, antithrombogenicity, especially at the portions thereof directly contacted with the blood. Should the artificial material exhibit low antithrombogenic in these portions, platelets tend to be accumulated to coagulate the blood to form blood clots, that is thrombus, which inhibits blood stream or which is moved with the blood stream to cause cerebral thrombosis, myocardial infarction or pulmonary infarction. Thus the formation of blood clots represents a serious problem to the human body.

Under these circumstances, various antithrombogenic materials have been evolved, such as polyurethane-silicone block polymers, heparinated high molecular materials, hydroxy ethyl methacrylate-styrene block polymer, urokinase immobilized high polymer material or plasma treated high molecular weight materials, for use in various fields of applications.

However, the first to fourth of these antithrombogenic material are prepared by chemical synthesis through various steps such as material refining or separation for synthesis with resulting inconveniences in productivity, equipment investments and costs.

The fifth material, which may be produced by physical processes, has a drawback that it presents a non-homogeneous treatment surface.

In short, the conventional antithrombogenic materials leave much to be desired in that the manufacture process is complicated or the product of a uniform quality cannot be produced without considerable difficulties.

OBJECTS AND SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide an antithrombogenic material which may be produced by a simple technique and which exhibits superior antithrombogenic.

The antithrombogenicity material of the present invention is characterized in that its surface has been modified by ion implantation and in that it consists of a silicone material which has its surface modified by introducing functional groups on its surface by ion implantation. With the antithrombogenic material of the present invention, compatibility to blood may be markedly improved by the introduction of the functional groups by ion implantation and by the doping effect of the implanted elements.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the Fourier Transform Infrared Spectrometry Attenuated Total Reflection (FT-IR-ART) spectrum on the silicone surface layer implanted with ions.

FIGS. 2A and 2B are charts showing the degree of platelet accumulation on the main organs of rats supplied with ion-implanted samples and on the samples in terms of the count ratio as measured with a scintillation counter.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present inventors have conducted eager searches for accomplishing the above object and reached the conclusion that ion implantation is highly effective in improving antithrombogenic.

The antithrombogenicity material of the present invention has been fulfilled on the basis of the above finding and is characterized in that the material has its surface modified by ion implantation.

Although there is no limitation to the artificial materials employed in the present invention, high molecular material, above all a silicone material is most preferred, and an antithrombogenicity material having superior compatibility with blood may be produced by modifying the silicone material through ion implantation.

Although the ion species such as O2 +, H+ and N2 + are preferred for implantation, such ions as He+, C+, N+, O+, Ne+, Na+, Ar+ or K+ may also be employed.

Although the amount of ions implanted and the energy for acceleration may be optically selected in dependence upon the usage or the species of the ions, they are usually selected to be in the range of about 1×1012 to 3×1017 cm-2 and in the range of tens to hundreds of keVs, respectively.

The possible reason for the improved antithrombogenic due to ion implantation is the introduction of a various functional groups into the artificial material, such as the silicone material, by the irradiation of the ion beams. The following Table 1 shows the species of functional groups generated in the silicone as a result of the ion implantation. Although OH groups are produced by implantation of any ion species, it is not clear if this is directly related with the antithrombogenic.

Although the doping effect of the implanted elements may be taken into consideration, it may be presumed that the introduction of the superficial functional groups and the doping are operating synergistically.

              TABLE 1______________________________________ion species  introduced functional groups______________________________________H.sup.+      SiOH,He.sup.+     SiOH, SiHC.sup.+      SiOH, SiH,      >C═ON.sup.+      SiOH, SiH,      amineO.sup.+      SiOH, SiH,      >C═ONe.sup.+     SiOH, SiH,Na.sup.+     SiOH, SiH, CH.sub.2                        carboxylateN.sub.2.sup.+        SiOH, SiH, CH.sub.2                        amineO.sub.2.sup.+        SiOH, SiH, CH.sub.2                        >C═OK.sup.+      SiOH, CH.sub.2  1560 cm.sup.-1Ar.sup.+     SiOH, SiH, CH.sub.2______________________________________

The present invention will be explained on the basis of concrete experimental results.

In the present experiment, H+, O2 + and N2 + were implanted in a silicone intended for medical use to test the compatibility thereof with the blood.

Sample

A silicone sheet for medical use, produced by the Toshiba Silicone Co. Ltd., was used as the material to be modified by ion implantation.

This silicone sheet has been prepared by thermally vulcanization cure of a polymer having a siloxane linkage Si-O in its main chain and side methyl chains CH3, as shown in the following structural formula, in the presence of a Pt catalyst: ##STR1##

Ion Implantation

Using a 200 kV ion implantation unit, prepared by Rikagaku Kenkyusho, H+, O2 + and N2 + ions were implanted at an acceleration energy of 150 keVs. The ion beam current of not more than 1 μA/cm2 was used to suppress a temperature rise in the sample. The amount of ions implanted was selected to be 2×1017 cm-2 and 1×1017 cm-2, for the ion species of H+ and O2 + or N2 +, respectively.

Chemical Properties of Ion Implantation Samples

The samples irradiated with the ion beam undergoes a variety of physical and chemical changes. By way of physical and chemical evaluation, measurements were made of the amounts of decomposition of the siloxane linkages and methyl groups as well as the superficial functional groups by the Fourier Transform Infrared Spectrometry Attenuated Total Reflection (FT-IT-ATR) method.

FIG. 1 shows a spectrum by FT-IR-ATR of a sample into which ions have not been implanted and a sample into which ions have been implanted for the wavelength range of 1300 to 4000 cm-1.

As may be seen from FIG. 1, various functional groups may be observed to have been produced on the surface layers of the samples in which ions have been implanted. Above all, OH group was yielded as a result of H+ implantation, OH and SiH groups and amine were produced as a result of N2 + implantation and OH, CH2, SiH and carbonyl groups were produced as a result of O2 + implantation. Most outstanding were the yielding of the amine and carbonyl groups by N2 + implantation O2 + implantation, respectively.

Evaluation by Antithrombogenic of the Ion-Implanted Samples

A rat was used as a laboratory animal. After platelets marked with a radioactive isotope (In-111 -tropolone) were intravenously administered to the rat under anesthetization, the ion-implanted sample was introduced into the superior vena cava via common carotid and retained there for two days.

The rat was then killed by loss of blood on heparin administration and the ion-implanted sample was well as the main organs were extracted. Using a scintillation counter, the radioactivity, i.e. the count ratio with respect to blood per unit weight, was measured of these samples and the main organs and the state of accumulation (formation of blood clots) was observed. Marking of the rat's platelets by In-111 -tropolone was performed in accordance with the Dewanjee et al's method.

FIGS. 2A and 2B show the count ratio of the In-111 -tropolone-platelet samples and the organs in rats not supplied with artificial blood vessel samples in the blood, rats supplied with artificial blood samples not implanted with ions, and rats supplied with artificial blood vessel samples implanted with ions, with respect to the samples and the organs.

With the rats supplied with artificial blood vessel samples not implanted with ions, platelet accumulation in the superior vena cava, hearts, samples, kidneys and livers was increased acutely as compared to that with the rats not supplied with the artificial blood vessel samples.

Conversely, with rats supplied with blood vessel samples in which H+ ions were implanted, platelet accumulation on the sample surface was decreased markedly. The same decreasing tendency was also noticed at the superior vena cava, hearts, kidneys and livers.

With rats supplied with artificial blood vessel samples in which N2 + ions were implanted, platelet accumulation was decreased at the superior vena cava, samples, hearts, kidneys and livers, whereas, with rats supplied with artificial blood vessel samples in which O2 + ions were implanted, platelet accumulation was decreased markedly in samples and superior vena cava and decreased in the hearts, kidneys and livers.

It may be seen from above that, with artificial blood vessel samples implanted with various ion species, platelet accumulation is markedly decreased on the sample surface with H+ ion implantation while it is markedly decreased not only on the sample but also in the superior vena cava with O2 + implantation. When platelet accumulation is decreased on the sample surface, it tends to be decreased in hearts, kidneys or livers as well, whereas, when platelet accumulation is decreased on the sample surface and in the superior vena cava, it is similarly decreased in the main organs.

Among the effects of retention of an artificial material in a living body are the formation of thrombus on the artificial material itself and platelet accumulation in the intrafiler organs. With H+ implantation, thrombus on the sample surface is suppressed, and platelet accumulates on the blood vessel wall. However, as compared to the artificial blood vessel sample in which N2 + ions are implanted, platelet accumulation on the blood vessel wall occurs to the same extent, whereas platelet accumulation on the liver occurs to a lesser extent. It may be seen that platelet accumulation on the intrafiler organs may be decreased due to the lesser damage inflicted on the platelets by contact with the artificial blood vessel samples. It may also be seen that the more the extent of suppression of platelet accumulation on the sample surface, the more the extent of suppression of platelet accumulation on the liver and the lesser the extent of damages inflicted on the platelets. Among the ion species employed in the present experiments, O2 + ions are most effective on suppressing platelet accumulation.

It is seen from above that the antithrombogenic material of the present invention exhibits superior compatibility to blood and affects the spleen, kidney or liver to a markedly lesser extent. This means that the damages done to the platelets within the living body have been decreased, which is of critical significance in not disturbing the living body system.

The antithrombogenic material of the present invention is manufactured by a surface treatment technique under thermally unbalanced conditions without employing chemical synthesis, so that no complicated process is necessitated with obvious advantages in productivity.

As compared to the manufacture by plasma processing, the direct effect is achieved while the uniformity and controllability are also excellent, since the interaction between the ion beam and the solid material is resorted to.

As compared to various conventional antithrombogenic materials, the antithrombogenic materials of the present invention may be manufactured easily by surface modification, and antithrombogenic may be advantageously improved by application to existing medical appliances.

Claims (15)

What is claimed is:
1. A biocompatible antithrombogenic device comprising:
a silicone material having an external surface; and
ions selected from the group consisting of H+, He+, Ne+, Na+, O2 +, K+, Ar+ and mixtures thereof implanted on the surface of the silicone material in sufficient quantity to substantially suppress platelet accumulation when exposed to blood.
2. A biocompatible antithrombogenic device comprising:
a silicone material having an external surface; and
functional groups selected from the group consisting of SiOH, SiH, CH2, CO, NH2, CO2 H and mixtures thereof on the external surface of the silicone material in sufficient quantity to substantially suppress platelet accumulation when exposed to blood.
3. The antithrombogenic device according to claim 2 wherein the functional groups are selected from the group consisting of CO, NH2 and mixtures thereof.
4. The antithrombogenic device according to claim 1 wherein the ions are selected from the group consisting of H30 , O2 + and mixtures thereof.
5. The antithrombogenic device material according to claim 2 wherein the silicone material is a polymer having the formula ##STR2##
6. The antithrombogenic device according to claim 4 wherein the ions are O2 + and CO functional groups are present on the silicone material surface.
7. The antithrombogenic device according to claim 4 wherein the ions are H+ and SiOH functional groups are present on the silicone material surface.
8. The antithrombogenic device according to claim 3 wherein the functional groups are NH2, SiOH or SiH and further comprising N2 + ions are implanted on the silicone material surface.
9. The antithrombogenic device according to claim 1 wherein the ions are He+ and on the silicone material surface SiOH or SiH functional groups are present.
10. The antithrombogenic device according to claim 2 wherein the functional groups are SiOH, SiH or CO and further comprising C+ ions are implanted on the silicone material surface.
11. The antithrombogenic device according to claim 1 wherein the ions are Ne+ and SiOH and SiH functional groups are present on the silicone material surface.
12. The antithrombogenic device according to claim 1 wherein the ions are Na+ and SiOH, SiH, CH2 and CO2 H functional groups are present on the silicone material surface.
13. The antithrombogenic device according to claim 1 wherein the ions are K+ and SiOH and CH2 functional groups are present on the silicone material surface.
14. The antithrombogenic device according to claim 1 wherein the ions are Ar+ and SiOH, SiH and CH2 functional groups are present on the silicone material surface.
15. The antithrombogenic device of claim 1 wherein the concentration of ions implanted on the silicone material surface is approximately between 1×1012 and 3×1017 per cm-2.
US07/570,614 1989-09-28 1990-08-21 Antithrombogenic material Expired - Lifetime US5152783A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP1-250523 1989-09-28
JP1250523A JP2930329B2 (en) 1989-09-28 1989-09-28 Anti-thrombotic material

Publications (1)

Publication Number Publication Date
US5152783A true US5152783A (en) 1992-10-06

Family

ID=17209159

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/570,614 Expired - Lifetime US5152783A (en) 1989-09-28 1990-08-21 Antithrombogenic material

Country Status (3)

Country Link
US (1) US5152783A (en)
JP (1) JP2930329B2 (en)
CA (1) CA2023964C (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308704A (en) * 1991-08-20 1994-05-03 Sony Corporation Cell adhesive material and method for producing same
US5334201A (en) * 1993-03-12 1994-08-02 Cowan Kevin P Permanent stent made of a cross linkable material
US5451428A (en) * 1991-05-21 1995-09-19 Hewlett-Packard Company Method for pretreating the surface of a medical device
WO1995031944A1 (en) * 1994-05-20 1995-11-30 Vec Tec, Inc. Methods rendering grafts nonthrombogenic and substantially nonimmunogenic
US5545208A (en) * 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5607463A (en) * 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
US5681575A (en) * 1992-05-19 1997-10-28 Westaim Technologies Inc. Anti-microbial coating for medical devices
US5837275A (en) * 1992-05-19 1998-11-17 Westaim Technologies, Inc. Anti-microbial materials
WO1998052623A1 (en) * 1997-05-22 1998-11-26 The Regents Of The University Of California Ion-implanted protein-coated intralumenal implants
US5851231A (en) * 1990-02-28 1998-12-22 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5906824A (en) * 1996-05-17 1999-05-25 Sony Corporation Antithrombogenic material and method for producing the same
WO2002074354A1 (en) * 2001-03-16 2002-09-26 Delsitech Oy Treatment of sols, gels, mixtures or composites of sols and gels, and/or sol-gel derived materials
WO2002094332A1 (en) * 2001-05-21 2002-11-28 Qualimed Innovative Medizinprodukte Gmbh Medical device
WO2004026355A1 (en) * 2002-08-30 2004-04-01 Riken Biological repair material compatible with biological tissue adhesive
US20040121451A1 (en) * 2001-03-16 2004-06-24 Niko Moritz Treatment of sols, gels and mixtures thereof
US20040176838A1 (en) * 2001-05-21 2004-09-09 Andreas Mucha Medical device
US20060058835A1 (en) * 1999-09-27 2006-03-16 Yuichi Murayama Bioabsorbable polymeric implants and a method of using the same to create occlusions
US20070185570A1 (en) * 2003-08-19 2007-08-09 The Chemo-Sero-Therapeutic Research Institute Material for aneurysm curing

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5636605A (en) * 1994-06-22 1997-06-10 Toyota Jidosha K.K. Composite intake manifold for an internal combustion engine
JP4327240B2 (en) * 2006-08-31 2009-09-09 新生化学工業株式会社 Printing method and a thermoplastic resin molded article of the resin molded body
JP4906548B2 (en) * 2007-03-15 2012-03-28 本田技研工業株式会社 Intake manifold for multi-cylinder internal combustion engines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808113A (en) * 1970-08-06 1974-04-30 Zaidan Hojin Seisan Kaihatsu K Method for manufacturing medical articles composed of various synthetic high polymers coated with collagen and exposed to radiation
US3903891A (en) * 1968-01-12 1975-09-09 Hogle Kearns Int Method and apparatus for generating plasma
US3955012A (en) * 1970-08-06 1976-05-04 Zaidan Hojin, Seisan Kaihatsu Kagaku Kenkyusho Method for manufacturing medical articles composed of silicone rubber coated with collagen
US4718905A (en) * 1986-08-13 1988-01-12 Freeman Jerre M Haptic element using ion beam implantation for an intraocular lens
US4851009A (en) * 1985-12-16 1989-07-25 Corvita Corporation Crack prevention of implanted prostheses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903891A (en) * 1968-01-12 1975-09-09 Hogle Kearns Int Method and apparatus for generating plasma
US3808113A (en) * 1970-08-06 1974-04-30 Zaidan Hojin Seisan Kaihatsu K Method for manufacturing medical articles composed of various synthetic high polymers coated with collagen and exposed to radiation
US3955012A (en) * 1970-08-06 1976-05-04 Zaidan Hojin, Seisan Kaihatsu Kagaku Kenkyusho Method for manufacturing medical articles composed of silicone rubber coated with collagen
US4851009A (en) * 1985-12-16 1989-07-25 Corvita Corporation Crack prevention of implanted prostheses
US4718905A (en) * 1986-08-13 1988-01-12 Freeman Jerre M Haptic element using ion beam implantation for an intraocular lens

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725567A (en) * 1990-02-28 1998-03-10 Medtronic, Inc. Method of making a intralumenal drug eluting prosthesis
US5851217A (en) * 1990-02-28 1998-12-22 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5851231A (en) * 1990-02-28 1998-12-22 Medtronic, Inc. Intralumenal drug eluting prosthesis
US6004346A (en) * 1990-02-28 1999-12-21 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5545208A (en) * 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5997468A (en) * 1990-02-28 1999-12-07 Medtronic, Inc. Intraluminal drug eluting prosthesis method
US5871535A (en) * 1990-02-28 1999-02-16 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5451428A (en) * 1991-05-21 1995-09-19 Hewlett-Packard Company Method for pretreating the surface of a medical device
US5308704A (en) * 1991-08-20 1994-05-03 Sony Corporation Cell adhesive material and method for producing same
US5681575A (en) * 1992-05-19 1997-10-28 Westaim Technologies Inc. Anti-microbial coating for medical devices
US5770255A (en) * 1992-05-19 1998-06-23 Westaim Technologies, Inc. Anti-microbial coating for medical devices
US5837275A (en) * 1992-05-19 1998-11-17 Westaim Technologies, Inc. Anti-microbial materials
US5985308A (en) * 1992-05-19 1999-11-16 Westaim Technologies, Inc. Process for producing anti-microbial effect with complex silver ions
US6238686B1 (en) 1992-05-19 2001-05-29 Westaim Technologies Anti-microbial coating for medical devices
US5753251A (en) * 1992-05-19 1998-05-19 Westaim Technologies, Inc. Anti-microbial coating for medical device
US5958440A (en) * 1992-05-19 1999-09-28 Westaim Technologies, Inc. Anti-microbial materials
US5334201A (en) * 1993-03-12 1994-08-02 Cowan Kevin P Permanent stent made of a cross linkable material
US5607463A (en) * 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
WO1995031944A1 (en) * 1994-05-20 1995-11-30 Vec Tec, Inc. Methods rendering grafts nonthrombogenic and substantially nonimmunogenic
US5906824A (en) * 1996-05-17 1999-05-25 Sony Corporation Antithrombogenic material and method for producing the same
US5891192A (en) * 1997-05-22 1999-04-06 The Regents Of The University Of California Ion-implanted protein-coated intralumenal implants
WO1998052623A1 (en) * 1997-05-22 1998-11-26 The Regents Of The University Of California Ion-implanted protein-coated intralumenal implants
US20060058835A1 (en) * 1999-09-27 2006-03-16 Yuichi Murayama Bioabsorbable polymeric implants and a method of using the same to create occlusions
US8388643B2 (en) 1999-09-27 2013-03-05 The Regents Of The University Of California Bioabsorbable polymeric implants and a method of using the same to create occlusions
WO2002074354A1 (en) * 2001-03-16 2002-09-26 Delsitech Oy Treatment of sols, gels, mixtures or composites of sols and gels, and/or sol-gel derived materials
US20040121451A1 (en) * 2001-03-16 2004-06-24 Niko Moritz Treatment of sols, gels and mixtures thereof
WO2002094332A1 (en) * 2001-05-21 2002-11-28 Qualimed Innovative Medizinprodukte Gmbh Medical device
US20040176838A1 (en) * 2001-05-21 2004-09-09 Andreas Mucha Medical device
WO2004026355A1 (en) * 2002-08-30 2004-04-01 Riken Biological repair material compatible with biological tissue adhesive
US20060155041A1 (en) * 2002-08-30 2006-07-13 Yoshiaki Suzuki Biological repair material compatible with biological tissue adhesive
US7722934B2 (en) 2002-08-30 2010-05-25 Riken Biological repair material compatible with biological tissue adhesive
US20070185570A1 (en) * 2003-08-19 2007-08-09 The Chemo-Sero-Therapeutic Research Institute Material for aneurysm curing
US20110196415A1 (en) * 2003-08-19 2011-08-11 Riken Material for aneurysm curing
US8268300B2 (en) 2003-08-19 2012-09-18 Riken Material for aneurysm curing

Also Published As

Publication number Publication date
CA2023964A1 (en) 2005-05-03
JPH03112560A (en) 1991-05-14
CA2023964C (en) 2005-05-03
JP2930329B2 (en) 1999-08-03

Similar Documents

Publication Publication Date Title
Banker et al. Water vapour transmission properties of free polymer films
Murphy et al. Encrustation and atherosclerosis: the analogy between early in vivo lesions and deposits which occur in extracorporeal circulations
Ferrans et al. Alcoholic cardiomyopathy a histochemical study
Bianchi Kinetics of radiocaffeine uptake and release in frog sartorius
Shulman et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients
Tanaka et al. Effect of water structure on blood compatibility—thermal analysis of water in poly (meth) acrylate
US3663288A (en) Physiologically acceptible elastomeric article
EP0329041B1 (en) Method for preparing lubricated surfaces
US6632470B2 (en) Methods for surface modification
US5182317A (en) Multifunctional thrombo-resistant coatings and methods of manufacture
US4812173A (en) Stabilized hydrogen peroxide contact lens disinfecting solution
Kamath et al. Surface chemistry influences implant‐mediated host tissue responses
Albuquerque et al. Effects of vinblastine and colchicine on neural regulation of the fast and slow skeletal muscles of the rat
US5108776A (en) Ocular implants and methods for their manufacture
Dekker et al. Adhesion of endothelial cells and adsorption of serum proteins on gas plasma-treated polytetrafluoroethylene
US5660873A (en) Coating intraluminal stents
DE60126697T2 (en) A process for producing a material for ocular lenses with a hydrophilic surface
Matlaga et al. Tissue response to implanted polymers: the significance of sample shape
Cserr et al. Extracellular volume decreases while cell volume is maintained by ion uptake in rat brain during acute hypernatremia.
Ross et al. Response to injury and atherogenesis.
Desai et al. Solution technique to incorporate polyethylene oxide and other water-soluble polymers into surfaces of polymeric biomaterials
Traub Persistence of lymphocytic choriomeningitis virus in immune animals and its relation to immunity
US4721800A (en) Biocompatible surfaces
US6248811B1 (en) Bioactive surface coating
McLellan et al. Increased effectiveness of substance abuse treatment: A prospective study of patient–treatment" matching."

Legal Events

Date Code Title Description
AS Assignment

Owner name: RIKAGAKU KENKYSHO, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SUZUKI, YOSHIAKI;KUSAKABE, MASAHIRO;IWAKI, MASAYA;AND OTHERS;REEL/FRAME:005474/0217

Effective date: 19900921

Owner name: SONY CORPORATION, A CORP. OF JAPAN, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SUZUKI, YOSHIAKI;KUSAKABE, MASAHIRO;IWAKI, MASAYA;AND OTHERS;REEL/FRAME:005474/0217

Effective date: 19900921

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12